Trial Profile
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Denagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 16 Oct 2005 New trial record.